JP2024540377A5 - - Google Patents
Info
- Publication number
- JP2024540377A5 JP2024540377A5 JP2024526890A JP2024526890A JP2024540377A5 JP 2024540377 A5 JP2024540377 A5 JP 2024540377A5 JP 2024526890 A JP2024526890 A JP 2024526890A JP 2024526890 A JP2024526890 A JP 2024526890A JP 2024540377 A5 JP2024540377 A5 JP 2024540377A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- polysorbate
- approximately
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163276363P | 2021-11-05 | 2021-11-05 | |
| US63/276,363 | 2021-11-05 | ||
| PCT/US2022/079072 WO2023081652A1 (en) | 2021-11-05 | 2022-11-01 | Pharmaceutical compositions of humanized anti-cd40 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540377A JP2024540377A (ja) | 2024-10-31 |
| JP2024540377A5 true JP2024540377A5 (enExample) | 2025-11-11 |
Family
ID=86242030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526890A Pending JP2024540377A (ja) | 2021-11-05 | 2022-11-01 | ヒト化抗ｃｄ４０抗体の医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20230279135A1 (enExample) |
| EP (2) | EP4785927A2 (enExample) |
| JP (1) | JP2024540377A (enExample) |
| KR (1) | KR20240095255A (enExample) |
| CN (1) | CN118382640A (enExample) |
| AU (1) | AU2022381078A1 (enExample) |
| CA (1) | CA3236827A1 (enExample) |
| MX (1) | MX2024005415A (enExample) |
| WO (1) | WO2023081652A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017040932A1 (en) | 2015-09-04 | 2017-03-09 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMP200800064B (it) * | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
| HUE065915T2 (hu) | 2011-03-11 | 2024-06-28 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antitestek és alkalmazásaik |
| WO2017040932A1 (en) * | 2015-09-04 | 2017-03-09 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
-
2022
- 2022-11-01 WO PCT/US2022/079072 patent/WO2023081652A1/en not_active Ceased
- 2022-11-01 JP JP2024526890A patent/JP2024540377A/ja active Pending
- 2022-11-01 CA CA3236827A patent/CA3236827A1/en active Pending
- 2022-11-01 KR KR1020247016673A patent/KR20240095255A/ko active Pending
- 2022-11-01 MX MX2024005415A patent/MX2024005415A/es unknown
- 2022-11-01 EP EP26170924.0A patent/EP4785927A2/en active Pending
- 2022-11-01 AU AU2022381078A patent/AU2022381078A1/en active Pending
- 2022-11-01 EP EP22890984.2A patent/EP4426744A4/en not_active Withdrawn
- 2022-11-01 US US18/051,807 patent/US20230279135A1/en not_active Abandoned
- 2022-11-01 CN CN202280075264.6A patent/CN118382640A/zh active Pending
-
2025
- 2025-05-23 US US19/216,990 patent/US20250282884A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016177A5 (enExample) | ||
| JP2024506940A5 (enExample) | ||
| JP2016534052A5 (enExample) | ||
| JP2024508762A5 (enExample) | ||
| ES2986900T3 (es) | Formulaciones de anticuerpos anti-cd3 | |
| JP2020518599A5 (enExample) | ||
| JP2022532927A5 (enExample) | ||
| JP2020518600A5 (enExample) | ||
| JP2024099682A5 (enExample) | ||
| JP2020509031A5 (enExample) | ||
| JP2020518598A5 (enExample) | ||
| RU2017107847A (ru) | Стабильный состав на основе антитела к il-4r-альфа | |
| JP7467438B2 (ja) | 抗ｒｓｖ抗体の製剤及びその使用方法 | |
| RU2015111341A (ru) | Композиции антитела и белка | |
| JP2020158505A5 (enExample) | ||
| JP2019504086A5 (enExample) | ||
| RU2010116152A (ru) | Антитело против рецептора il-6 | |
| JP2025032102A5 (enExample) | ||
| JP2014510152A5 (enExample) | ||
| JP2017515909A5 (enExample) | ||
| JP2013531679A5 (enExample) | ||
| JP2024544523A5 (enExample) | ||
| WO2019055357A1 (en) | METHOD FOR THE LYOPHILIZED PHARMACEUTICAL FORMULATION OF A THERAPEUTIC PROTEIN | |
| JP2015510882A5 (enExample) | ||
| JP2022151814A5 (enExample) |